Brokers Offer Predictions for ALGS Q1 Earnings

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Aligos Therapeutics in a report released on Wednesday, April 15th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($1.27) per share for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q2 2027 earnings at ($1.29) EPS, Q3 2027 earnings at ($0.84) EPS and Q4 2027 earnings at ($0.85) EPS.

ALGS has been the subject of several other reports. UBS Group started coverage on shares of Aligos Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price target for the company. Jefferies Financial Group raised shares of Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday, March 26th. Wall Street Zen lowered shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Westpark Capital started coverage on shares of Aligos Therapeutics in a research note on Thursday, March 26th. They issued a “buy” rating and a $48.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aligos Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

Aligos Therapeutics Stock Performance

Shares of NASDAQ ALGS opened at $7.66 on Friday. Aligos Therapeutics has a 52-week low of $4.20 and a 52-week high of $13.69. The firm has a 50 day moving average price of $7.29 and a two-hundred day moving average price of $8.52. The stock has a market cap of $47.42 million, a P/E ratio of -0.89 and a beta of 2.62.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.09) by $0.18. The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.27 million. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%.

Hedge Funds Weigh In On Aligos Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ALGS. Geode Capital Management LLC lifted its holdings in shares of Aligos Therapeutics by 21.3% in the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after acquiring an additional 5,978 shares during the last quarter. Rockefeller Capital Management L.P. grew its position in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after buying an additional 9,000 shares during the period. NorthCrest Asset Manangement LLC purchased a new stake in shares of Aligos Therapeutics in the 3rd quarter worth about $98,000. Susquehanna International Group LLP purchased a new stake in shares of Aligos Therapeutics in the 3rd quarter worth about $99,000. Finally, LPL Financial LLC grew its position in Aligos Therapeutics by 19.7% during the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock valued at $615,000 after purchasing an additional 10,880 shares during the last quarter. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.